OS Therapies Incorporated OSTX
Set alert
At close · Oct 30
After hours · Oct 30, 7:42 PM ET
- YTD
- -11.43%
- 1 year
- -29.94%
- Open
- 1.27
- Prev close
- 1.30
- Mkt cap
- 58.04M
- Vol
- 321.73K
- Avg vol
- 588.38K
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.21
- High
- 1.28
- Forward P/E
- 2.57
- Beta
- 0.00
- Short ratio
- 1.22
- Inst. own
- 0.75%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.72
- 200-d avg
- 3.11
- 1y target
- 12.67
News
1 week ago newsfilecorp.com
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestones Company expects to complete early…
3 weeks ago globenewswire.com
Rubenstein Public Relations Named Agency of Record for OS Therapies
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rubenstein Public Relations (RPR), a leading full-service communications firm, announces it has been named the Agency of Record for OS Therapies, Inc.…
-
3 weeks ago benzinga.com
OS Therapies' OSAH Subsidiary Receives U.S. Department Of Agriculture Guidance On Commercial Deployment Pathway For OST-HER2 To Treat Canine Osteosarcoma
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its wholly-owned animal health…
3 weeks ago feeds.newsfilecorp.com
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
Received notice for upcoming USDA meetingCompany is reviewing strategic alternatives to monetize OS Animal Health ("OSAH")Grasonville, Maryland--(Newsfile Corp. - October
3 weeks ago benzinga.com
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
OS Therapies Inc. (NYSE:OSTX) announced a statistically significant three-year overall survival benefit for patients treated with OST-HER2 in its Phase 2b trial.
3 weeks ago benzinga.com
OS Therapies Reports Significant Three-Year Survival Data for Bone Cancer Treatment
OS Therapies reports a 72.7% three-year survival rate in its Phase 2b osteosarcoma trial, preparing for global regulatory submissions.
-
3 weeks ago benzinga.com
OS Therapies Announces Statistically Significant Final 3-Yr Overall Survival Benefit For OST-HER2-Treated Patients In Phase 2b Trial In Pulmonary Metastatic Osteosarcoma Compared With Combined Published Historical Control
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p…
3 weeks ago newsfilecorp.com
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients 72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control…
-
1 month ago benzinga.com
OS Therapies Appoints Frank Knuettel II As CFO
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced the appointment of Kerry Clem as Chief…
1 month ago newsfilecorp.com
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate Herlystic™(OST-HER2; daznelimgene lisbac) Grasonville,…
1 month ago newsfilecorp.com
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited,…
-
1 month ago benzinga.com
OS Therapies Provided an Update on Global Early Market Access Regulatory Coordination Efforts By UK's MHRA For OST-HER2 For Pulmonary Metastatic Osteosarcoma Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing…
1 month ago newsfilecorp.com
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K. with existing Phase 2 drug product paved the way Conditional Marketing…
-
1 month ago benzinga.com
OS Therapies Achieves Incremental FDA Alignment Regarding Its Biologics License Application For OST-HER2 For Prevention Or Delay Of Recurrence In Fully-Resected, Pulmonary Metastatic Osteosarcoma
The Company aligned with the FDA on the use of the proposed adaptive design agreed upon with the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency…
1 month ago newsfilecorp.com
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trial After successful Scientific Advice Meeting, Company accepts MHRA request to become he Company's' sponsor into Project Orbis to…
-
1 month ago benzinga.com
OS Therapies Achieves Full Alignment With UK MHRA On Its Pending Conditional Marketing Authorization Application
MHRA agreed that the use of comparable historical control data – derived from a systematic evaluation of all suitable available peer-reviewed literature by independent biostatistics advisors…
1 month ago newsfilecorp.com
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissions Full alignment achieved on confirmatory Phase 3 trial design Complete CMAA submission expected in…
1 month ago benzinga.com
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
OS Therapies (NYSE: OSTX) interim Phase 2b trial data shows a 71.2% 3-year overall survival rate for OST-HER2 vs. 45.8% for controls.
-
1 month ago benzinga.com
OS Therapies Announces Statistically Significant Benefit For OST-HER2-Treated Patients In An Interim 3-Year Overall Survival Data Analysis
Overall survival data when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the Company's Phase 2b trial for the prevention or…
1 month ago newsfilecorp.com
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002) The two remaining patients who have not yet reached the 3-year timepoint from…
2 months ago newsfilecorp.com
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development…
2 months ago newsfilecorp.com
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical…
-
2 months ago benzinga.com
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-September
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT…
2 months ago newsfilecorp.com
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT…
-
3 months ago benzinga.com
Roth Capital Initiates Coverage On OS Therapies with Buy Rating, Announces Price Target of $7
Roth Capital analyst Adam Walsh initiates coverage on OS Therapies (AMEX:OSTX) with a Buy rating and announces Price Target of $7.
-
3 months ago benzinga.com
OS Therapies Accepts New FDA Meeting Request For Review Of Pharmacodynamic Response Biomarker Data
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request…
3 months ago newsfilecorp.com
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods Meeting New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS…
-
3 months ago benzinga.com
OS Therapies Expects Phase 3 Study For The OST-HER2 Metastatic Osteosarcoma Program To Begin Near End Of Q3 2026
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The
3 months ago newsfilecorp.com
OS Therapies Third Quarter 2026 Corporate Outlook
Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market…
4 months ago newsfilecorp.com
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Company secures $10 million line of credit supported by OS Therapies UK tax credits New York, New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American:…
-
4 months ago benzinga.com
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's
4 months ago newsfilecorp.com
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall…
-
4 months ago benzinga.com
OS Therapies Announces Peer-Reviewed Publication Of Data From Its Phase 2 Clinical Trial Of OST-HER2 With Palliative Radiation Therapy To Prevent Amputation In Frontline Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed with osteosarcomaCompany expects to submit U.S. Department of Agriculture meeting…
4 months ago newsfilecorp.com
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995) Over 15,000 dogs per year diagnosed with osteosarcoma Company expects to submit U.S. Department of Agriculture…
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
4 months ago benzinga.com
OS Therapies Achieves FDA And UK MHRA Alignment On Design Of Its Pending Phase 3 Study Of OST-HER2 For Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and AustraliaPatent pending pharmacodynamic response…
4 months ago newsfilecorp.com
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and Australia Patent pending pharmacodynamic response…
5 months ago benzinga.com
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings
OS Therapies shares rise after OST-HER2 Phase 2b data showed a 75% survival rate and progress toward FDA, EMA and TGA regulatory filings.
-
5 months ago benzinga.com
OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year Mark
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated…
-
5 months ago benzinga.com
Lake Street Maintains Buy on OS Therapies, Lowers Price Target to $13
Lake Street analyst Chad Messer maintains OS Therapies (AMEX:OSTX) with a Buy and lowers the price target from $14 to $13.
-
5 months ago benzinga.com
OS Therapies Q1 EPS $(0.27) Misses $(0.18) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.18) by 50 percent. This is a 50 percent decrease over losses of $(0.18) per…
-
6 months ago benzinga.com
OS Therapies Says EMA's CAT Initiates Continuous Evaluation Of OST-HER2 CMA Request Regulatory Dossier For Prevention Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating…
-
6 months ago benzinga.com
OS Therapies Files New Patent Application Covering Immune Signature In Response Therapeutic Candidates Developed Using Listeria Monocytogenes Platform
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responsesCompany to host conference…
-
7 months ago benzinga.com
OS Therapies Q4 EPS $(0.41) Misses $(0.13) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.13) by 228 percent. This is a 70.83 percent decrease over losses of $(0.24)…
-
7 months ago benzinga.com
OS Therapies Completes Filing On Clinical, Biomarker Data From Its Phase 2b Clinical Study Of OST-HER2 To FDA
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it has completed the submission on clinical and…
-
7 months ago benzinga.com
OS Therapies Engages Four Global Regulators In Q2 2026 Ahead Of Phase 3 Osteosarcoma Trial Enrollment Expected To Begin In Australia
Meetings with all four regulatory agencies scheduled to occur in the second quarter of 2026, with expected Phase 3 commencement in the third quarter of 2026 initially in AustraliaCommencing the Phase…
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
7 months ago benzinga.com
OS Therapies Advances OST‑HER2 Toward BLA; FDA Elevates Meeting To Type B Pre‑BLA
FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussionsOS Therapies on track to complete clinical data submission by the end of Q1 2026New…
8 months ago benzinga.com
OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings
OS Therapies shares climb after new regulatory plans for OST-HER2 osteosarcoma treatment in the UK, EU, and U.S.